The three-way partnership aims to increase the robustness and reduce costs for the manufacturing of adeno-associated virus (AAV) vectors, a delivery vehicle used for emerging gene therapy treatments.
The gene therapy area has been developing rapidly and while only a small number of treatments are already approved for use, more than 200 clinical trials are underway.
GE Healthcare’s Puridify fibre-based chromatography technology platform, can achieve high purification productivity of protein biopharmaceuticals, such as monoclonal antibodies. The collaboration with CPI and Cobra Biologics will help demonstrate the application of the purification platform to gene therapy, helping to provide more efficient and scalable gene therapy manufacturing and more affordable therapies.
The project will extend the advantages of GE Healthcare’s technology and develop a multistep fibre-based chromatography purification process for AAV, reports the collaborators. These viral vectors will be produced in-house by Cobra Biologics and CPI using a system developed via an ongoing Innovate UK grant. The developed fibre-based technology will then be transferred to CPI, where entire process flowsheets incorporating the technology will be run to demonstrate suitability for AAV manufacture.
“We are proud to establish this collaboration with Cobra and CPI that seeks to advance technologies for the manufacture of viral vectors that are necessary for emerging gene therapies. Collaboration and bringing together expertise from different fields is critical for improving access to these promising new treatments globally,” says Dr. Oliver Hardick, Business Leader, Puridify, GE Healthcare Life Sciences.